New drug combo aims to tame rare blood cancer, prepares for future fight
NCT ID NCT00492050
Summary
This study tested a two-drug combination (bortezomib and rituximab) as a first treatment for people with Waldenstrom's macroglobulinemia, a rare blood cancer. The main goals were to see if the treatment could control the disease and safely collect patients' own stem cells. These collected cells could be used later for a transplant if the cancer worsened.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM'S MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.